Meeting
2012 ASCO Annual Meeting
The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.
Authors
Ramon Salazar
Institut Catala d'Oncologia, Barcelona, Spain
Ramon Salazar , John Marshall , Jaume Capdevila , Bengt Glimelius , Jan Willem de Waard , Jacobus Van Der Hoeven , Joost Klaase , Frédéric Bibeau , Thomas Bachleitner-Hofmann , Rachel A Midgley , Edward Allen Levine , Wai Lun Law , Michio Asano , George J. Chang , Stephen M Cohen , Robert W. Beart , Paul M. Goldfarb , Martin McCarter , Lisette Stork-Sloots , Robert Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Clinical Trial Registration Number
NCT00903565
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS10632)
DOI
10.1200/jco.2012.30.15_suppl.tps10632
Abstract #
TPS10632
Poster Bd #
54A
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
First Author: Ramon Salazar
Poster
2011 Gastrointestinal Cancers Symposium
The PARSC trial: A prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
First Author: Ramon Salazar
Poster
2011 ASCO Annual Meeting
The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
First Author: R. Salazar
Poster
2014 ASCO Annual Meeting
Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.
First Author: Ramon Salazar